Hydrocephalus as the sole presentation of primary diffuse large B-cell lymphoma of the brain: Report of a case and review of literature.

CONCLUSION: In this communication, we intend to highlight the issue that hydrocephalus refractory to several interventions can be the sole manifestation of PCNSL and needs special clinical considerations. PMID: 28840069 [PubMed]
Source: Surgical Neurology International - Category: Neurosurgery Tags: Surg Neurol Int Source Type: research

Related Links:

We present two cases which are specific for unusual location of Burkitt lymphoma in the colon and stomach, in immunocompetent patients with negative Epstein-Barr virus tests. Also, one of the patients presented is one of the oldest ever reported with abdominal Burkitt lymphoma, while the other patient is an example of diagnostic difficulties in distinguishing Burkitt lymphoma from similar lymphomas. Due to the rapidly growing tumors and urgent need for cytoreductive surgery, it is crucial to consider the diagnosis of Burkitt lymphoma even in atypical localizations or absence of the common risk factors associated with Burki...
Source: Acta Clinica Croatica - Category: General Medicine Tags: Acta Clin Croat Source Type: research
Conditions:   Stem Cell Transplant Complications;   Myeloma;   Lymphoma;   Allogeneic and Autologous Stem Cell Transplant Interventions:   Other: physical therapy consult;   Other: Cognitive Assessment;   Other: Cancer Aging Research Group (CARG) assessment;   Other: Medication Review;   Other: Nutrition assessment;   Other: Laboratory studies;   Other: Patient satisfaction questionnaire;   Other: Physician Q uestionnaire;   Other: Pati...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
A 29-year-old woman with stage IIBX classic Hodgkin's lymphoma presented with a 5.1  × 7.6-cm (mass to mediastinal ratio 0.34) anterior mediastinal mass and additional involvement of the subcarinal, posterior mediastinal, and right infraclavicular lymph nodes (Fig. 1). The patient was otherwise healthy, a lifelong nonsmoker, and European Cooperative Oncology Group performance s tatus 0. She had a National Comprehensive Cancer Network International Prognostic Score of 1. She received 2 cycles of adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD), and interim positron emission tomography demonstr...
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Gray Zone Source Type: research
The patient in question, with both B symptoms and bulky disease, belongs to an intermediate group in which disease can be considered advanced and treated with bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone if we follow the German Hodgkin's Study HD 11 criteria.1 Many others still treat this group as an early unfavorable disease using doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). This is particularly important in explaining the treatment options presented here.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Gray Zone Source Type: research
This young patient could be classified as having unfavorable early-stage Hodgkin lymphoma (HL) per the European Organization for Research and Treatment of Cancer H10 study or advanced HL per UK Response-Adapted Therapy for Advanced Hodgkin Lymphoma study, both adaptive therapy trials commencing with 2  cycles of Doxorubicin, bleomycin, vinblastine, and dacarbazine.1
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Gray Zone Source Type: research
Peculiar Unpleasant Dysgeusia as the Sole Initial Symptom of Guillain-Barré Syndrome. Intern Med. 2019 Dec 06;: Authors: Nakamura T, Tsukita K, Suzuki A, Watanabe G, Harada R, Kawasaki E, Chiba T, Sugaya R, Suzuki Y Abstract Dysgeusia is rare in Guillain-Barré syndrome, particularly as the initial symptom. We herein report the case of a 59-year-old woman who presented with only dysgeusia as the initial symptom of Guillain-Barré syndrome, followed by gradually worsening muscle weakness and bilateral sensory disturbances in the extremities. Her dysgeusia was so unpleasant that she co...
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
AbstractPersistence of human immunodeficiency virus 1 (HIV-1) latency and residual immune activation remain major barriers to treatment in patients receiving highly active antiretroviral therapy (HAART). In the present study, we investigated the molecular mechanisms of persistent HIV infection and residual immune activation in HAART-treated patients. We showed that the expression level of B-cell CLL/lymphoma 11B (BCL11B) was significantly increased in CD4+T cells from HIV-infected patients undergoing HAART, and this was accompanied by increased expression of BCL11B-associated chromatin modifiers and inflammatory factors in...
Source: Archives of Virology - Category: Virology Source Type: research
Dr. Hamori recently addressed concerns over BIA-ALCL in this video." ALCL (Anaplastic large cell lymphoma) is a very rare disease, found in approximately one in 30,000 patients. So, while there is a lot of hype about it right now, and while I think it is important that women are aware of it, it is also creating a lot of panic for a disease that is quite uncommon.First of all, it affects only people who have textured implants — implants that have a little pebbling on the outside. The theory is that after seven or eight years contamination can occur, some over reactive immune response occurs, a fluid film for...
Source: What's New In Plastic Surgery? - Category: Cosmetic Surgery Tags: bia-alcl breast implant disease Source Type: blogs
ConclusionsThe findings of this study support the usefulness of PET/CT in the detection of subcutaneous MZL, and in staging and treatment decisions.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 9 December 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Yilin Chen, Hua Yin, Lifeng Chen, Yingyuan Xiong, Li Meng, Jingming Guo, Haiyan Wang, Weiming LiAbstractTo investigate the real-life choice of first-line treatment in the chronic phase of chronic myeloid leukemia (CML-CP) and the feasibility of switching to nilotinib treatment strategy after first-line imatinib. We went through retrospective analysis of the efficacy and safety of imatinib versus nilotinib for first-line for CML-CP patients, and comparative analysis of the efficacy of sustained imatinib versus switchin...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Aphasia | Brain | Cancer & Oncology | Hydrocephalus | Lymphoma | Neurology | Primary CNS Lymphoma | Shunt for Hydrocephalus